With a 4-year follow-up, first-line pembrolizumab and pembrolizumab-chemotherapy continued to demonstrate survival benefit versus cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Patients responded well to subsequent treatment after pembrolizumab-based therapy.
No takes yet. Share an insight, caveat, or question.
Harrington et al. (2022) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: